Notably, PIK3CA—part of the PI3K-AKT pathway—ranked among the top hubs, suggesting it may play a pivotal role in AS-IV’s therapeutic effects against IPF. The gene discussed is PIK3CA; the disease is idiopathic pulmonary fibrosis.